Thermo Fisher Scientific Inc. $TMO Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Thermo Fisher Scientific by 101.1% in Q1, acquiring an additional 35,809 shares, bringing its total holdings to 71,214 shares valued at approximately $35.44 million.
• Analysts have varied ratings for Thermo Fisher Scientific, with Robert W. Baird raising its target price from $553 to $567 and others issuing "hold" ratings, resulting in an average target price of $589.38.
• Thermo Fisher Scientific announced a quarterly dividend of $0.43 per share, representing an annual yield of 0.3%, with the payment date set for October 15th.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 101.1% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 71,214 shares of the medical research company's stock after buying an additional 35,809 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Thermo Fisher Scientific were worth $35,436,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Port Capital LLC lifted its stake in Thermo Fisher Scientific by 1.6% in the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after acquiring an additional 22 shares during the last quarter. Clark Capital Management Group Inc. lifted its stake in Thermo Fisher Scientific by 0.5% in the fourth quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock worth $2,312,000 after acquiring an additional 23 shares during the last quarter. Monograph Wealth Advisors LLC lifted its stake in Thermo Fisher Scientific by 0.3% in the fourth quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock worth $4,507,000 after acquiring an additional 23 shares during the last quarter. Finally, Intergy Private Wealth LLC lifted its stake in Thermo Fisher Scientific by 5.8% in the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock worth $208,000 after acquiring an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TMO. HSBC restated a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research report on Friday, July 11th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Finally, Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $592.24.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $14.18 during trading hours on Thursday, reaching $490.72. The company's stock had a trading volume of 848,813 shares, compared to its average volume of 2,399,717. The stock has a market cap of $185.30 billion, a PE ratio of 28.41, a PEG ratio of 2.58 and a beta of 0.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The company's 50-day moving average is $464.58 and its two-hundred day moving average is $452.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.